Posts Tagged :

imaging biomarkers

QUIBIM Imaging Biomarkers made transparent

QUIBIM, AI imaging disruption to showcase the value of Precision

We are in the era of Precision Medicine, and so is Radiology. Nowadays, main imaging modalities like X-ray, computed tomography (CT), magnetic resonance (MR), positron emission tomography (PET) and hybrid machines, among others, have become measurement instruments. Images are not only pictures anymore, but thanks to the application of computational analysis and artificial intelligence, they are data, as you can learn in this excellent manuscript in Radiology.

Nowadays, when radiologists perform measurements of different organs, tissues and lesion properties using a workstation, they are used to get a number (i.e. lesion volume or perfusion). If they take the same images and they get to analyze them in a workstation from another vendor (not straightforward), it is pretty sure that they will obtain different results. This issue has introduced a sense of lack of standardization and homogenization in the quantitative medical imaging field.

I like to say that value is to trust in the product, and we have decided to be the first company in the world to open the validation process and tests results of our imaging biomarkers. Every time we buy a measurement device for daily life purposes (i.e. thermometer) we know the degree of uncertainty, why wouldn’t we do the same in AI algorithms and quantitative imaging?

We are proud to make this announcement at ECR 2018: Now it is possible to see the precision, accuracy and clinical evaluation results of our imaging biomarkers. We provide the precision (through Coefficient of Variation, CoV) and accuracy (through relative error, e) values through the publication of QUIBIM Technical Datasheets that you can find in the resources section of our webpage.

With this strategy QUIBIM is going a step further by being the first multi-vendor, web-based and real precision Medicine company of the medical imaging & AI market.

Concerned by the accuracy of your measurements? Let’s work together.

Quibim Team


  • En 2015 fue una de las 27 startups aceleradas en la 3ª edición del programa Lanzadera.

  • Quibim es una Spin-Off del Instituto de Investigación Sanitaria La Fe.

Valencia, 28/07/17.- La empresa biotecnológica Quibim se refuerza mediante la entrada de Angels – la sociedad de inversión perteneciente a Marina de Empresas e impulsada por el empresario Juan Roig – en el capital social de la compañía.

Tras la ronda a finales de 2016 con el Fondo de Inversión Tecnológico Tech Transfer UPV, AYCE Capital, Bioinfogate y los promotores del proyecto; y la ayuda H2020 Instrumento Pyme Fase II, de la que ha sido beneficiaria recientemente; Quibim recibe el apoyo de Angels, que participa en la empresa mediante la capitalización del préstamo que la compañía tenía con Lanzadera.

Impulsada por Ángel Alberich Bayarri, CEO, y el Dr. Luis Martí Bonmatí, radiólogo de reconocido prestigio internacional, director del Área Clínica de Imagen Médica del Hospital Universitario y Politécnico La Fe de Valencia y actual director del Consejo Científico de la empresa; la compañía está formada en la actualidad por 11 personas.

Quibim es una empresa biotecnológica especializada en la extracción de información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear, mediante técnicas originales y avanzadas de procesamiento computacional. Estos parámetros extraídos reciben el nombre de Biomarcadores de Imagen y aportan rasgos extraídos de las imágenes médicas, relacionadas con procesos biológicos normales, enfermedades o respuestas terapéuticas.

Además, el equipo ha desarrollado la plataforma Quibim Precision® de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía, TAC, Resonancia Magnética o PET, Quibim es capaz de aplicar avanzados algoritmos de análisis que incluyen metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de Quibim permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos.

Según afirma Ángel Alberich-Bayarri, “La entrada de Angels en la compañía es para nosotros una gran satisfacción, ya que se materializa la relación iniciada en nuestro paso por Lanzadera, cuya ayuda fue imprescindible para hacer este proyecto realidad”.

El Director General de Angels, Jaime Esteban, añade, “Contar con Quibim entre las participadas de Angels afianza lo que Marina de Empresas quiere significar para los emprendedores: un lugar donde recibir apoyo en cualquier momento de su carrera, desde la formación hasta la inversión”.


Sobre Angels

Angels es la sociedad de inversión perteneciente a Marina de Empresas e impulsada por el empresario Juan Roig con capital 100% privado. Desde su constitución en septiembre de 2013, ha aportado a diferentes proyectos emprendedores más de 12 millones de € para que estas empresas de nueva generación puedan crecer y desarrollar su actividad. En la actualidad, Angels participa además de en Quibim, en Codigames, Grupo Sothis, Instituto Valenciano del Pie (IVPie), Grupo Vintes (Bodega Torre Oria), viVood y PlayFilm.


QUIBIM granted with the H2020 – SME Instrument Phase II

QUIBIM team is proud to announce that the beneficiaries of the European Commission SME Instrument Phase 2 have been recently published, and our project has been awarded in the Open Disruptive Innovation (ODI) topic.

QUIBIM’s project “QUIBIM Precision” has been granted with 1.25M€ for the scaling and development of the company business plan through our cloud platform QUIBIM Precision®. This funding will boost and accelerate the strategic plan of the company, bringing new disruptive solutions to our platform, including dedicated High Performance Computing resources for our Machine Learning processes, incorporating new visual analytics tools and helping validate new imaging biomarkers that have been recently developed.

QUIBIM Precision® is an innovative imaging biomarker analysis platform in the cloud allowing for:

  1. Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and reproducibility.
  2. Medically certified: QUIBIM is medically valid to scientifically support decision making.
  3. Open to any physicians: Optimized User Interface (UI), user experience (UX) and imaging analysis functionalities.
  4. Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis.

Our technology based on machine learning and image processing algorithms scouts the image and compares it to similar images in our database with known ground-truth diagnosis, based on patterns not obvious to a human eye.

QUIBIM is a biotechnology company dedicated to advanced medical image analysis. It was one of the start-ups selected in the 3rd edition of the acceleration program “LANZADERA” and it’s a spin-off company of the Medical Research Institute Hospital La Fe. Recently the company closed an investment round to boost its growth, including Tech Transfer UPV, AYCE Capital, and BioInfoGate, as well as some company promoters . QUIBIM’s business model is based on the extraction of quantitative information from radiological and nuclear medicine imaging using original and advanced computational processing techniques.

In 2016, QUIBIM was also selected as one of the disruptive companies by the EU and granted with the first round of Horizon 2020 SME Instrument Phase I Program 2016 under the call: “SMEInst-01- 2016-2017: Open Disruptive Innovation Scheme”

SME instrument – Horizon 2020 call
The SME Instrument is divided into 3 phases covering different stages of the innovation cycle. Phase 1 aims to cover the assessment of technical feasibility and market potential of new ideas. The project will be supported by an investment of 50,000€ and the typical duration should be no longer than 6 months.

Phase 2 aims to cover R&D activities with a particular focus on demonstration activities (testing, prototype, scale-up studies, design, piloting innovative processes, products and services, validation, performance verification etc.) and market replication encouraging the involvement of end users or potential clients. Project funding should amount to no more than 2,500,000€ and the typical duration of this phase should range from 12 to 24 months.

QUIBIM at BIO 2017

QUIBIM in BIO 2017

Our company was present again this year in the incredibly huge BIO International Convention in San Diego, California, from June 19th to 22nd. Our registration included both a booth at the Spanish pavilion and the access to the One-to-One partnering meetings.

We had 15 planned meetings and many other new contacts thanks to the interaction at our exhibitor space with agents interested in QUIBIM business model. We made several demonstrations of QUIBIM Precision platform and image analysis capabilities in clinical trials. From all the contacts and meetings performed at BIO, I wanted to point out the classification we found according to their profile:

  • Scientific parks and incubators (30%)
  • Investors in Life Sciences (20%)
  • CRO’s and Pharma companies (50%)

From our experience last year in San Francisco, in this edition there has been a higher interest from scientific parks and incubators beyond Boston and Silicon Valley to attract companies to their facilities, showing the benefits of establishing the companies in specific locations, specially in the different states of US. The number of investors stayed similar, but we have been an increasing interest in the field of Medical Devices. Regarding CRO’s and Pharma companies, most of them are progressively considering medical imaging in their clinical trials, and the best, considering us for their solutions. We are so proud to cover those unmet needs on advanced image analysis services for Clinical Trials, allowing pharma companies, CRO’s and Principal Investigators to follow-up in real time their study. In fact, one of the main trends at BIO this year was how data processing will change the way new drugs are developed and launched into market.

QUIBIM CEO (Angel Alberich-Bayarri) & Booth at BIO 2017

QUIBIM CEO (Angel Alberich-Bayarri) & Booth at BIO 2017


We were so glad to have this exhibitor space at the Spanish pavilion, and compared to previous editions, it was also the first time that the Valencia region had a dedicated area inside it (similar to Biocat from Catalonia and Biobasque from Basque Country). The Valencia area was organised by IVACE (Instituto Valenciano para la Competitividad Empresarial), and the organism was represented by Mrs. Mónica Payá (representative for foreign investment of IVACE). The Principe Felipe Research Centre (CIPF), was also represented by Oscar David Sánchez (Projects and Technology Transfer Manager).

Valencia region representatives at BIO 2017 in San Diego, Angel Alberich (QUIBIM), Mónica Payá (IVACE), Daniel Calvo (BIOPOLIS), Marisol Quintero (Biooncotech)

Valencia region representatives at BIO 2017 in San Diego, Angel Alberich (QUIBIM), Mónica Payá (IVACE), Daniel Calvo (BIOPOLIS), Marisol Quintero (Biooncotech)


Valencia region representatives at BIO 2017 in San Diego, Óscar David Sánchez (CIPF), Mónica Payá (IVACE), Daniel Calvo (BIOPOLIS), Angel Alberich-Bayarri (QUIBIM)

Valencia region representatives at BIO 2017 in San Diego, Óscar David Sánchez (CIPF), Mónica Payá (IVACE), Daniel Calvo (BIOPOLIS), Angel Alberich-Bayarri (QUIBIM)


All the days at BIO were so productive that there is a significant work to be done at home, contacting back with the people we met and following up these new relationships.

Obviously not everything is work and there is also some spare time for entertainment at BIO, in the following picture, a rock band playing at the middle of Gaslamp quarter in San Diego. The streets were closed to welcome BIO 2017 participants in a nice evening with food, drink and music, a nice experience!

Band performing at BIO 2017 in middle of Gaslamp quarter

Band performing at BIO 2017 in middle of Gaslamp quarter

Lymphatic system

Imaging Biomarkers in Lymphoma

Imaging has a crucial role in Lymphoma management nowadays. The main applications are based on the evaluation of disease extension in staging and in treatment response evaluation. Recently, thanks to the technology development of PET-CT and CT scanners, it has shown also a high utility in the evaluation of extra-nodular involvement, the early relapse and the transformation from indolent Lymphoma to an aggressive phenotype [1].

Evidence sets PET-CT and standard CT+contrast as the main imaging modalities for staging and treatment response evaluation. The most suitable modality will depend mainly on the aggressiveness and the FDG avidity of the lesion. Therefore, either for Hodgkin’s Lymphoma (HL), aggressive subtypes of non-Hodgkin’s Lymphoma (NHL) or for extra-nodal involvement evaluation in PET-CT will be the way to go for an appropriate staging. However, in cases of non-FDG avidity, mainly in indolent lymphomas (T-cell lymphoma and subtypes of NHL like Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma), contrast enhanced CT is the main modality. Regarding response evaluation, a similar distribution of lymphoma subtypes per modalities is arrange, with the difference in the Follicular Lymphoma (FL), where PET-CT is the most suitable technique for those FL with a high tumoral burden, whereas low tumoral burden FL should be studied by CT with contrast when studying response. Up to now, Magnetic Resonance Imaging (MRI) has still not shown enough evidence in the management of lymphoma patiens beyond Primary Brain Lymphoma. PET-MR has a promising future in Lymphoma evaluation, specially in the current need for low dose follow-up studies that could be done with this modality.

Imaging Applications in Lymphoma

Imaging Applications in Lymphoma


Due to heterogeneities in FDG metabolic uptake in different Lymphoma subtypes, Deauville criteria were established to grade the avidity in comparison with mediastinum and liver. However, conventional PET-CT has limitations in the staging of nodular alterations, with the exception of FL, where PET-CT helps to increase the stage of Lymphoma by detecting additional disease in up to 29% of cases. Regarding response evaluation, PET-CT has been recently considered as the gold standard at end of treatment in FL. This is one of the main conclusions from GALLIUM study.

Despite the previous comments, we understand that the staging and response evaluation in PET-CT in patients under new treatments based on targeted therapies or immunotherapy can not be only based on SUVmax evaluations. New imaging biomarkers have been developed in order to evaluate complex clinical scenarios like indolent Lymphoma or reactive inflammatory changes at the end of treatment in patients that have responded to therapy.

In the following table, specific Imaging Biomarkers for different biological objectives are provided:

Objetive Modality Imaging Biomarker
Tumoral burden PET-CT Metabolic Tumor Volume (MTV)
Tumoral burden + Metabolic activity PET-CT Total Tumor Glycolisis (TTG)
Change in metabolic activity PET-CT Voxelwise Delta-SUV (ΔSUV)
Heterogeneity CT & PET-CT Textures

For Imaging Biomarkers implementation, we always follow the step-wise method that we developed and published and that was also considered in this European Society of Radiology guideline.

The first technical step of Imaging Biomarkers development workflow after an appropriate definition of the idea is the Images Acquisition. In PET-CT, European Association of Nuclear Medicine (EANM) guidelines should be followed, and centres should be ideally certified by EARL program.

Metabolic Tumor Volume (MTV)

The first Imaging Biomarker to be calculated is MTV. It is defined by consensus as those lesion voxels with a significant FDG uptake, that is >41% of SUVmax although different thresholds can be evaluated in practise. The typical units are cm^3. The analysis is performed semi-automatically by thresholding and manual correction.

Calculation of Metabolic Tumor Volume

Calculation of Metabolic Tumor Volume


Several studies have analysed MTV values in different types of lymphoma, in the following table from Schöder H. J Clin Onc 2016, a nice summary can be appreciated:

Schöder H, Moskowitz C. Metabolic Tumor Volume in Lymphoma: Hype or Hope? J Clin Oncol. 2016 Sep 6. pii: JCO693747. [Epub ahead of print] PubMed PMID: 27601547.

Schöder H, Moskowitz C. Metabolic Tumor Volume in Lymphoma: Hype or Hope? J
Clin Oncol. 2016 Sep 6. pii: JCO693747. [Epub ahead of print] PubMed PMID:

The different thresholds used for MTV can be also appreciated (although 41% SUVmax is the one in the majority of them). Also, the wide range of MTV obtained show us the high heterogeneity of the disease and raises also the concern about treatment dose. Should we modulate the treatment given to patient by the MTV? or, on another way, does a patient with 600cm^3 of MTV have to receive the same treatment dose than a patient with 3000cm^3 ? Important research needs still to be done in this field.

Regarding MTV and Follicular Lymphoma, few studies have been performed. The most important one was a retrospective analysis from Meignan et al, where they calculated a MTV of 510cm^3 for 2-year Progression Free Survival (PFS). However, some controversy has arose mainly due to the fact that the inherent error in SUV measurements due to examination variability introduces a final MTV error in measurements around 20%, so the threshold should not be a single value, but a given range of MTV values that consider that error.


Total Tumor Glycolysis (TTG)

The TTG measurements is better applied for specific lesions rather than all lesion burden. Therefore, if we focus on specific lesions, the TTG combines information on the FDG avidity and the MTV of the lesion by the following equation:

TTG = MTV x SUVmean


Voxelwise delta-SUV 

The structural and anatomic information contained in the CT examination within the PET-CT acquisition can be used for spatial registration of scans of the same patient corresponding to different timepoints (e.g. registration of end-of-treatment CT on baseline CT). The idea behind this is to create a parametric map of the longitudinal SUV changes in the patient, and for that the deformation field resulting from spatial registration is applied to the end-of-treatment PET in order to convert it to the baseline geometry. After this process, the follow-up examination can be superimposed to the baseline and therefore even substracted to calculate the SUV difference between timepoints.

delta-SUV pipeline

delta-SUV pipeline


Textures analysis

The image regions can be also evaluated quantitatively by means of texture analysis. Texture analysis allows for the extraction of quantitative descriptors from voxel intensities relationships within an image or region. They are organised in first order (if directly extracted from histogram) or second order (if an additional step is required for their calculation). Texture analysis and specially heterogeneity biomarkers like the entropy and kurtosis have shown promising results in many different cancerous lesions, specially as a prognostic biomarker.

Texture analysis from lymphoma lesion in CT

Texture analysis from lymphoma lesion in CT

In lymphoma, a recent manuscript from Ganeshan B. et al. has shown excellent results in providing complimentary information to the interim PET as a prognostic biomarker.

However, texture analysis techniques can also be applied to other type of images such as the PET component, being able to determine the metabolic heterogeneity (MH) of the lesions. In this regard, lesions with different regional FDG avidity are having a worse prognosis than lesions with a homogeneous FDG uptake.

Metabolic Heterogeneity in FDG uptake in lymphoma

Metabolic Heterogeneity in FDG uptake in lymphoma


As you have discovered in this post, there are still many Quantitative Imaging Biomarkers that can be extracted from conventional FDG PET-CT examinations, and which are showing important relationship with lymphoma progression, according to recent investigations. In QUIBIM we are a committed team dedicated to the implementation of these techniques in clinical practise, research and clinical trials. If you want to collaborate with us in this field do not hesitate to contact us and potentially upload a case through our QUIBIM Precision® platform. It will be the best way to start working together in this emerging field.



Quibim Team

We are Hiring! Do you want to be a Quibimer?

We are excited to announce that we are seeking an Engineer to join our fantastic team in Valencia.

What do we need?

  • Enginner with 1-2 years of experience in the field of software development and medical imaging (biomedical, Computing, Electronics)
  • Experience as Java Developer
  • Experience with SQL databases
  • Experience in web development based on API-REST
  • Experience with GIT version control
  • Experience in application deployment with Apache Tomcat
  • Fluent english

Our ideal candidate’ Skills & Experience…

  • Experience with Spring or Jersey frames
  • Experience in integrating external APIs
  • Experience with the dcm4che library
  • Test Driven Development Experience (TDD / BDD)
  • Experience with the DICOM and HL7 standards
  • Experience in integration with PACS and RIS systems
  • Experience in developing CLI applications

What is a plus?

  • Experience with the C ++, Python or NodeJS languages
  • Experience as a FrontEnd
  • Experience with NoSQL databases
  • Experience with Microsoft Azure

If you are proactive, dynamic and forward thinking profile Apply Here



Quibim Precision V2.0

It is a real pleasure for Quibim to announce the release of Precision 2.0. On this new version, we have focused on improving its performance, making it more powerful and user friendly. Keep reading to know how we did it…
read more

quibim_imaging-biomarkers_funding round

QUIBIM cierra una ronda de inversión de 550.000€

La financiación permitirá a la empresa mejorar su plataforma de análisis de imágenes médicas y su comercialización


Valencia, 27 de diciembre de 2016. QUIBIM S.L, empresa biotecnológica de análisis avanzado de imágenes médicas, ha anunciado el cierre de su primera ronda de financiación por un valor de 550.000 euros de la mano de Tech Transfer UPV, AYCE Capital, Bioinfogate y los propios promotores de la compañía.

Se trata de la primera empresa de España en cerrar una ronda de inversión con un fondo de transferencia tecnológica asociado a una Universidad Pública: TechTransfer UPV, cuya finalidad es la creación y consolidación de empresas con elevado potencial de crecimiento, procedentes del ámbito investigador. Esta ronda de inversión permitirá a la empresa acelerar el desarrollo y comercialización del producto para seguir creciendo como compañía referente en la gestión y procesado de imagen médica en el ámbito hospitalario e industria farmacéutica,  promoviendo así, su consolidación nacional y expansión internacional.

Con sede en Valencia, la empresa, que es Spin-Off del Instituto de Investigación Sanitaria La Fe, fue fundada en 2012 e impulsada por Ángel Alberich-Bayarri y el Dr. Luis Martí Bonmatí tras una larga trayectoria de investigación y desarrollo. Ángel Alberich-Bayarri es Dr. Ingeniero Biomédico por la Universidad Politécnica de Valencia y es el CEO de QUIBIM. Luis Martí-Bonmatí es un radiólogo de reconocido prestigio internacional y es el Director del Área Clínica de Imagen Médica del Hospital Universitario y Politécnico La Fe de Valencia.

El modelo de negocio de QUIBIM (Quantitative Imaging Biomarkers in Medicine) se  basa  en  la  extracción  de  información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear mediante técnicas originales y avanzadas de procesamiento  computacional. Para Alberich-Bayarri, QUIBIM tiene por objetivo: “mejorar  los  procesos  de  diagnóstico  de  enfermedades  con  alta  incidencia y  evaluar  adecuadamente  los  cambios  que  producen  los tratamientos farmacológicos en el organismo, para  aportar  así,  diagnósticos  mucho  más certeros y precoces, complementando de manera cuantitativa y medible la valoración cualitativa que se realiza a partir del ojo del radiólogo en la Medicina actual”.

QUIBIM fue una de las start-ups valencianas seleccionadas en la 3ª edición del programa Lanzadera, promovido por el Presidente de Mercadona, Juan Roig. El programa Lanzadera permitió impulsar a la empresa con formación y asesoramiento, así como con una financiación aproximada de 200.000€.

La startup ha desarrollado una plataforma de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía , TAC, Resonancia Magnética o PET, QUIBIM es capaz de aplicar avanzados algoritmos de análisis que incluyen metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de QUIBIM permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos.

La compañía comercializa diferentes modelos de análisis para hospitales, empresas farmacéuticas y radiólogos. Para 2017 mantiene un presupuesto de ventas de 500.000€ de los cuales a fecha de hoy tiene ya comprometido el 30%.

Según afirma Ángel Alberich-Bayarri: “Estamos muy satisfechos con el cierre de esta ronda porque supone un gran impulso para nosotros, la financiación nos permitirá mejorar nuestra plataforma de análisis y su comercialización. Además, los inversores no aportan únicamente el capital, sino también su experiencia en el sector biotecnológico, lo que nos es de especial relevancia en esta fase de crecimiento”.

Por su parte, Pedro de Álava, director del Fondo Tech Transfer UPV, ha destacado que “la imagen médica está revolucionando la medicina al aportar soluciones personalizadas, precisas y predictivas del comportamiento de las enfermedades. Y el proyecto de QUIBIM reúne talento, disciplina técnica y escalabilidad, lo que genera un amplio valor para hospitales, empresas farmacéuticas y pacientes”.

El Dr. José Mateos, especialista en diagnóstico por imagen y director médico de Imagen Ensayos Clínicos S.L (IEC) empresa líder en la gestión de imagen en ensayos clínicos con más de 10 años de experiencia aportando valor a los estudios promocionados por los principales laboratorios farmacéuticos y CROs a nivel internacional, ha explicado “Durante los últimos 3 años estamos creciendo y consolidando nuestra posición a nivel local y nacional. La inversión actual de nuestra compañía en Quibim y las sinergias ya establecidas hace unos meses entre ambas empresas nos situarán como referentes indispensables en ensayos clínicos a nivel nacional e internacional”.

El Dr Jose Prous, Director Ejecutivo de BioInfoGate y cofundador del Prous Institute for Biomedical Research subrayó: “Los biomarcadores de imagen constituyen un elemento clave para optimizar el descubrimiento, desarrolllo y aplicación clínica de fármacos más eficaces y seguros. En la nueva era de la medicina de precisión, los innovadores métodos analíticos desarrollados por QUIBIM, permitirán optimizar el abordaje terapéutico de múltiples enfermedades.”

Sobre Tech Transfer UPV, f.c.r

Tech Transfer UPV es el primer fondo de transferencia de tecnología impulsado dentro del sistema universitario español que apuesta por proyectos de transferencia de tecnología y emprendimiento generados en la Universitat Politècnica de València para acompañarlos en su salida al mercado.

Tras este primer cierre de inversión, dispone de un patrimonio de 3,9 millones de euros. El Fondo está participado por 28 empresarios y profesionales valencianos y de Castellón de diferentes sectores que, además de invertir, participan como validadores de los proyectos. Entre ellos, el Instituto Valenciano de Finanzas, Caixa Popular Productos Citrosol, Air Nostrum, Grupo IVI, Multiscan, ACAL, Arca Telecom, S2 Grupo, Miarco, La Unión Alcoyana Seguros, Nero Family, Blast of partners, Tecnopaking, Vik Consultoría o Ca&CCA ingeniería.

Sobre AYCE Capital e Imagen en Ensayos Clínicos S.L.

AYCE Capital es una gestora friendly Business Angels de Barcelona que trabaja con proyectos de sectores muy distintos: servicios, healthcare, industrial, retail, cultura, agro-alimentario, TIC…

IEC es inversor en QUIBIM de la mano de AYCE Capital

Sobre Bioinfogate


BIOINFOGATE ( es una spin-off del Prous Institute for Biomedical Research ( , con sede en Barcelona. La empresa ha sido creada con el objetivo de dinamizar la investigación en biomedicina y tecnologías médicas mediante el uso intensivo de metodologías de “Data Science” (big data) y bases de datos especializadas.

Las soluciones desarrolladas por el grupo Prous han sido utilizadas con éxito, durante los últimos 50 años, por científicos de todo el mundo en el descubrimiento de nuevos fármacos. Primero desde Prous Science (adquirida por Thomson Reuters en 2007) empresa líder mundial en el desarrollo de bases de datos (Integrity) y publicaciones de química médica (Drug of the Future) y posteriormente desde el Prous Institute for Biomedical Research mediante el desarrollo de sistemas expertos en predicción de seguridad y toxicidad de fármacos (Symmetry) y la invención de nuevas moléculas para el tratamiento de enfermedades neurodegenerativas, cáncer y diabetes.

Los productos del grupo Prous se utilizan diariamente en todas las  organizaciones relacionadas con las ciencias de la salud incluyendo industrias farmacéuticas y de biotecnología, centros de investigación públicas y privados y agencias reguladoras como la U.S. Food and Drug Adminstration (FDA).

Complementariamente a los desarrollos propios, Bioinfogate invierte en proyectos emergentes que se alinean con nuestro negocio principal en ciencias de la vida y análisis de datos.

quibim_imaging-biomarkers_funding round

QUIBIM closes a seed funding round of €550,000

The funding will allow the company to improve the platform for medical image analysis and work in marketing and sales strategy


Valencia, 27 December 2016. QUIBIM SL is a biotechnology company dedicated to advanced medical image analysis that has announced the closing of its first round of funding worth 550,000 euros shared by Tech Transfer UPV, AYCE Capital, and Bioinfogate, besides the own promoters of the company.

It is the first company in Spain to close an investment round with a technology transfer fund associated with a Public University: TechTransfer UPV, whose purpose is the creation and consolidation of companies with high potential for growth, from the research field. This round of investment will enable the company to accelerate the development and commercialization of the product to continue to grow as a leading company in the management and processing of medical images for hospitals and the pharmaceutical industry, thus promoting its national consolidation and international expansion.

Based in Valencia (SPAIN), the company, which is Spin-Off of the Institute of Health Research La Fe, was founded in 2012 and promoted by Angel Alberich-Bayarri and Dr. Luis Martí Bonmatí after a long history of research and development. Ángel Alberich-Bayarri is PhD in Biomedical Engineering from the Polytechnic University of Valencia and is the CEO of QUIBIM. Luis Martí-Bonmatí is an international Key Opinion Leader in Radiology and is the Director of the Clinical Area of ​​Medical Image of the Hospital Universitario y Politécnico La Fe in Valencia.

The business model of QUIBIM (Quantitative Imaging Biomarkers in Medicine) is based on the extraction of quantitative information of medical images in radiology and nuclear medicine through original and advanced computer processing techniques. For Alberich-Bayarri, QUIBIM aims to: “improve the diagnostic processes of diseases with high incidence and adequately evaluate the changes that produce the pharmacological treatments in the organism, to contribute to much more accurate and early diagnoses, complementing in a quantitative and measurable way the qualitative valuation that is performed from the eye of the radiologist in today Medicine”.

QUIBIM was one of the start-ups valencianas selected in the 3rd edition of the acceleration program, promoted by the President of Mercadona, Juan Roig. The program allowed to boost the company with training and mentoring, as well as with a funding of approximately € 200,000.

The startup has developed a platform for medical image analysis in the cloud, which can be installed in private versions for hospitals and pharmaceutical companies to develop clinical trials. By using X-ray images, Ecography, CT, MRI or PET scans, QUIBIM is able to apply advanced analysis algorithms including GPU-based (graphics processing units) processing, or Big Data and Machine Learning methodologies. The QUIBIM software allows to provide more information in the diagnoses and to be able to evaluate in an early way the response to the pharmacological treatments.

The company markets different analytical models for hospitals, pharmaceutical companies and radiologists. For 2017 maintains a sales budget of 500,000 € of which to date has already committed 30%.

According to Angel Alberich-Bayarri: “We are very satisfied with this funding round because it is a great boost for us, the financing will allow us to improve our analysis platform and its commercialization. In addition, investors do not only contribute capital, but also their experience in the biotechnology sector, which is of special relevance to us in this phase of growth”

Pedro de Álava, director of the Tech Transfer UPV Fund, stressed that “the medical images are revolutionizing medicine by providing personalized, accurate and predictive solutions to the behavior of diseases. And the QUIBIM project brings together talent, technical discipline and scalability, which generates a wide value for hospitals, pharmaceutical companies and patients.”

Dr. José Mateos, a specialist in image diagnosis and medical director of Imagen Ensayos Clínicos SL (IEC), a leading company in image management in clinical trials with more than 10 years of experience, adding value to the studies promoted by the main pharmaceutical laboratories and CROs at the international level, stated “During the last 3 years we are growing and consolidating our position at local and national level. The current investment of our company in Quibim and the synergies already established a few months ago between both companies will place us as indispensable references in clinical trials at national and international level.”

Dr Jose Prous, Executive Director of BioInfoGate and co-founder of the Prous Institute for Biomedical Research, emphasized: “Imaging biomarkers are a key element in optimizing the discovery, development and clinical application of more effective and safe drugs. In the new era of precision medicine, the innovative analytical methods developed by QUIBIM will allow optimizing the therapeutic approach to multiple diseases. “

About Tech Transfer UPV, fcr

Tech Transfer UPV is the first transfer fund of technology promoted within the Spanish university system that bets on projects of technology transfer and entrepreneurship generated at the Universitat Politècnica de València to accompany them on their way out to the market.

After this first investment closure, it has a net worth of 3.9 million euros. The Fund is represented by 28 Valencian and Castellón businessmen and professionals from different sectors who, in addition to investing, participate as validators of the projects. Among them, the Valencian Institute of Finance, Caixa Popular, Productos Citrosol, Air Nostrum, Grupo IVI, Multiscan, ACAL, Arca Telecom, S2 Group, Miarco, La Unión Alcoyana Seguros, Nero Family, Blast of partners, Tecnopaking, Vik Consulting or Ca & CCA engineering.

About AYCE Capital e Imagen en Ensayos Clínicos SL

AYCE Capital is a friendly business angels manager from Barcelona who works with projects from very different sectors: services, healthcare, industrial, retail, culture, agri-food, ICT …

IEC is an investor in QUIBIM by the hand of AYCE Capital

About Bioinfogate

BIOINFOGATE ( ) is a spin-off of Prous Institute for Biomedical Research ( ), based in Barcelona. The company has been created with the aim of boosting research in biomedicine and medical technologies through the intensive use of “Big Data” methodologies and specialized databases.

The solutions developed by the Prous group have been used successfully over the last 50 years by scientists worldwide in the discovery of new drugs. First from Prous Science (acquired by Thomson Reuters in 2007), the world’s leading developer of Integrity and Drug of the Future publications, and later from the Prous Institute for Biomedical Research through the development of systems Experts in safety prediction and drug toxicity (Symmetry) and the invention of new molecules for the treatment of neurodegenerative diseases, cancer and diabetes.

The products of the Prous group are used daily in all organizations related to the health sciences including biotechnology and pharmaceutical industries, public and private research centers and regulatory agencies such as the US Food and Drug Adminstration (FDA).

In addition to our own developments, Bioinfogate invests in emerging projects that are aligned with our core business in life sciences and data analysis.